SG11201900400QA - Bispecific antibody-like binding proteins specifically binding to cd3 and cd123 - Google Patents
Bispecific antibody-like binding proteins specifically binding to cd3 and cd123Info
- Publication number
- SG11201900400QA SG11201900400QA SG11201900400QA SG11201900400QA SG11201900400QA SG 11201900400Q A SG11201900400Q A SG 11201900400QA SG 11201900400Q A SG11201900400Q A SG 11201900400QA SG 11201900400Q A SG11201900400Q A SG 11201900400QA SG 11201900400Q A SG11201900400Q A SG 11201900400QA
- Authority
- SG
- Singapore
- Prior art keywords
- sanofi
- main
- frankfurt
- deutschland gmbh
- international
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization 1#11101111 0 11101 HOE 3E1 0 01111113 10111001110110111011011# International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2018/015340 Al 25 January 2018 (25.01.2018) WIP0 I PCT (51) International Patent Classification: C07K 16/28 (2006.01) A61K 39/00 (2006.01) FRANKFURT AM MAIN (DE). KROLL, Katja; c/ o sanofi-aventis Deutschland GmbH, 65926 FRANK- A61K 39/395 (2006.01) FURT AM MAIN (DE). LANGE, Christian; c/o sanofi- (21) International Application Number: aventis Deutschland GmbH, 65926 FRANKFURT AM MAIN (DE). LEUSCHNER, Wulf Dirk; c/o sanofi-aven- PCT/EP2017/068020 tis Deutschland GmbH, 65926 FRANKFURT AM MAIN (22) International Filing Date: (DE). RAO, Ercole; c/o sanofi-aventis Deutschland GmbH, 17 July 2017 (17.07.2017) 65926 FRANKFURT AM MAIN (DE). SCHNEIDER, Marion; c/o sanofi-aventis Deutschland GmbH, 65926 (25) Filing Language: English FRANKFURT AM MAIN (DE). WONEROW, Peter; c/ (26) Publication Language: English o sanofi-aventis Deutschland GmbH, 65926 FRANKFURT (30) Priority Data: AM MAIN (DE). GUERIF, Stephane; c/o Sanofi, Patent 16305923.1 18 July 2016 (18.07.2016) EP Department, 54 me la Boetie, 75008 Paris (FR). (74) Agent: TINEL, Marie-Line; c/o Sanofi, Patent Depart- (71) Applicant: SANOFI [FR/FR]; 54 me La Boetie, 75008 PARIS (FR). ment, 54 me La Boetie, 75008 PARIS (FR). (81) Designated States (unless otherwise indicated, for every (72) Inventors: ALBRECHT, Jana; c/o sanofi-aventis kind of national protection available): AE, AG, AL, AM, Deutschland GmbH, 65926 FRANKFURT AM MAIN AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (DE). BEIL, Christian; c/o sanofi-aventis Deutschland CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, — GmbH, 65926 FRANKFURT AM MAIN (DE). BENIN- DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, GA, Jochen; c/o sanofi-aventis Deutschland GmbH, 65926 HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, = Title: BISPECIFIC ANTIBODY-LIKE BINDING PROTEINS SPECIFICALLY BINDING TO CD3 AND CD123 (54) = = A B = r1 I g2 , 3i = KD .azr IVO = _ 245 i = 190 kl 135 100 ,„,, w 1 = 80 *ft Mil — = '4' = 58 2,1,0 1 46 ,.„„ . 32 . at I i wen = = _ = 25 lis i . Ate toT 22 ..., 17 .... R iu 11 .-44 — ,—, FIG.2 © 7r M 11 in (57) : The present invention concerns antibody-like binding protein specifically binding to CD3 and CD123. The invention also C ,—, - --- GC relates to pharmaceutical compositions comprising said antibody-like binding protein and the use of said pharmaceutical compositions , 1 and antibody-like binding protein to treat cancer. The invention further relates to isolated nucleic acids, vectors and host cells comprising 0 a sequence encoding said antibody-like binding protein. ei C [Continued on next page] WO 2018/015340 Al MIDEDIMOMOIDEIREIDIONIM11011100H0110EVOIS KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a))
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16305923 | 2016-07-18 | ||
PCT/EP2017/068020 WO2018015340A1 (en) | 2016-07-18 | 2017-07-17 | Bispecific antibody-like binding proteins specifically binding to cd3 and cd123 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201900400QA true SG11201900400QA (en) | 2019-02-27 |
Family
ID=56507555
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201900400QA SG11201900400QA (en) | 2016-07-18 | 2017-07-17 | Bispecific antibody-like binding proteins specifically binding to cd3 and cd123 |
Country Status (24)
Country | Link |
---|---|
US (1) | US20190241657A1 (en) |
EP (1) | EP3484924A1 (en) |
JP (2) | JP7071329B2 (en) |
KR (1) | KR20190028771A (en) |
CN (1) | CN109715665A (en) |
AR (1) | AR109264A1 (en) |
AU (1) | AU2017299125A1 (en) |
BR (1) | BR112019000770A2 (en) |
CA (1) | CA3030943A1 (en) |
CL (1) | CL2019000119A1 (en) |
CO (1) | CO2019001367A2 (en) |
CR (1) | CR20190072A (en) |
DO (1) | DOP2019000011A (en) |
EA (1) | EA201990321A1 (en) |
EC (1) | ECSP19011185A (en) |
IL (1) | IL264248A (en) |
MA (1) | MA45680A (en) |
MX (1) | MX2019000844A (en) |
PE (1) | PE20190514A1 (en) |
PH (1) | PH12019500122A1 (en) |
SG (1) | SG11201900400QA (en) |
TN (1) | TN2019000015A1 (en) |
TW (1) | TWI790206B (en) |
WO (1) | WO2018015340A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TN2017000275A1 (en) | 2015-01-23 | 2018-10-19 | Sanofi Sa | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 |
JO3792B1 (en) | 2015-07-31 | 2021-01-31 | Amgen Res Munich Gmbh | Antibody constructs for flt3 and cd3 |
TWI796283B (en) | 2015-07-31 | 2023-03-21 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for msln and cd3 |
EA039859B1 (en) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Bispecific antibody constructs binding egfrviii and cd3 |
CA3118081A1 (en) * | 2018-10-30 | 2020-05-07 | Macrogenics, Inc. | Bispecific cd123 x cd3 diabodies for the treatment of hematologic malignancies |
BR112021017801A2 (en) * | 2019-03-11 | 2022-01-18 | Janssen Biotech Inc | Bispecific anti-vbeta17/anti-cd123 antibodies |
CN111171155B (en) * | 2020-02-05 | 2021-02-19 | 北京智仁美博生物科技有限公司 | anti-CD 3 and CD123 bispecific antibodies and uses thereof |
TW202200619A (en) * | 2020-03-17 | 2022-01-01 | 美商西雅圖免疫公司 | Guidance and navigation control (gnc) antibody-like proteins and methods of making and using thereof |
JP2024506831A (en) | 2021-01-28 | 2024-02-15 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Compositions and methods for treating cytokine release syndrome |
CN113368232B (en) * | 2021-06-02 | 2022-08-26 | 上海交通大学 | Multispecific antigen binding proteins and uses thereof |
CA3224408A1 (en) * | 2021-08-06 | 2023-02-09 | Rosalba LEPORE | Discernible cell surface protein variants for use in cell therapy |
WO2023201226A1 (en) | 2022-04-11 | 2023-10-19 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4361549A (en) | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
JPS6023084B2 (en) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | blood substitute |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
JPS63502716A (en) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | How to enhance glycoprotein stability |
US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
EP0497883B1 (en) | 1989-10-27 | 1998-07-15 | Arch Development Corporation | Compositions and their use for promoting immunopotentiation |
US6406696B1 (en) | 1989-10-27 | 2002-06-18 | Tolerance Therapeutics, Inc. | Methods of stimulating the immune system with anti-CD3 antibodies |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
AU9166691A (en) | 1990-12-20 | 1992-07-22 | Ixsys, Inc. | Optimization of binding proteins |
EP0689601B1 (en) | 1993-02-22 | 2006-10-04 | The Rockefeller University | Production of high titer helper-free retroviruses by transient transfection |
US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
FR2712812B1 (en) | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition for the production of therapeutic products in vivo. |
IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
JP3946256B2 (en) | 1995-09-11 | 2007-07-18 | 協和醗酵工業株式会社 | Antibody to human interleukin 5 receptor α chain |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
US6177078B1 (en) | 1995-12-29 | 2001-01-23 | Medvet Science Pty Limited | Monoclonal antibody antagonists to IL-3 |
DE19721700C1 (en) | 1997-05-23 | 1998-11-19 | Deutsches Krebsforsch | Mutant OKT3 antibody |
DE69909459T2 (en) | 1998-04-21 | 2004-05-27 | Micromet Ag | CD19XCD3 SPECIFIC POLYPEPTIDES AND THEIR USE |
US6733743B2 (en) | 2000-03-06 | 2004-05-11 | University Of Kentucky Research Foundation | Methods to impair hematologic cancer progenitor cells and compounds related thereto |
CN111909273A (en) | 2007-08-29 | 2020-11-10 | 塞诺菲-安万特股份有限公司 | Humanized anti-CXCR 5 antibodies, derivatives thereof and uses thereof |
EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
KR101837053B1 (en) * | 2008-10-01 | 2018-03-12 | 암젠 리서치 (뮌헨) 게엠베하 | Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxcd3, igf-1rxcd3 or fapalphaxcd3 bispecific single chain antibody |
TWI622597B (en) | 2011-03-28 | 2018-05-01 | 賽諾菲公司 | Dual variable region antibody-like binding proteins having cross-over binding region orientation |
MX352101B (en) | 2011-08-23 | 2017-11-08 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules. |
HUE059815T2 (en) * | 2012-05-18 | 2022-12-28 | Aptevo Res & Development Llc | Bispecific scfv immunofusion (bif) binding to cd123 and cd3 |
EP2839842A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
BR112016009617A2 (en) * | 2013-12-10 | 2017-09-19 | Hoffmann La Roche | USE OF A CONJUGATE OF A BINDER DOMAIN AND METHOD FOR TARGETED DELIVERY OF A POLYPEPTIDE |
WO2016036937A1 (en) * | 2014-09-05 | 2016-03-10 | Janssen Pharmaceutica Nv | Cd123 binding agents and uses thereof |
RS62332B1 (en) * | 2014-11-26 | 2021-10-29 | Xencor Inc | Heterodimeric antibodies that bind cd3 and cd20 |
TN2017000275A1 (en) * | 2015-01-23 | 2018-10-19 | Sanofi Sa | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 |
-
2017
- 2017-07-14 TW TW106123588A patent/TWI790206B/en active
- 2017-07-17 SG SG11201900400QA patent/SG11201900400QA/en unknown
- 2017-07-17 AU AU2017299125A patent/AU2017299125A1/en not_active Abandoned
- 2017-07-17 MX MX2019000844A patent/MX2019000844A/en unknown
- 2017-07-17 TN TNP/2019/000015A patent/TN2019000015A1/en unknown
- 2017-07-17 EA EA201990321A patent/EA201990321A1/en unknown
- 2017-07-17 CA CA3030943A patent/CA3030943A1/en active Pending
- 2017-07-17 EP EP17749380.6A patent/EP3484924A1/en not_active Withdrawn
- 2017-07-17 MA MA045680A patent/MA45680A/en unknown
- 2017-07-17 PE PE2019000065A patent/PE20190514A1/en not_active Application Discontinuation
- 2017-07-17 US US16/318,599 patent/US20190241657A1/en not_active Abandoned
- 2017-07-17 CR CR20190072A patent/CR20190072A/en unknown
- 2017-07-17 KR KR1020197004345A patent/KR20190028771A/en not_active Application Discontinuation
- 2017-07-17 CN CN201780056945.7A patent/CN109715665A/en active Pending
- 2017-07-17 BR BR112019000770A patent/BR112019000770A2/en not_active IP Right Cessation
- 2017-07-17 AR ARP170101993A patent/AR109264A1/en unknown
- 2017-07-17 JP JP2019502257A patent/JP7071329B2/en active Active
- 2017-07-17 WO PCT/EP2017/068020 patent/WO2018015340A1/en unknown
-
2019
- 2019-01-15 IL IL264248A patent/IL264248A/en unknown
- 2019-01-16 PH PH12019500122A patent/PH12019500122A1/en unknown
- 2019-01-16 DO DO2019000011A patent/DOP2019000011A/en unknown
- 2019-01-16 CL CL2019000119A patent/CL2019000119A1/en unknown
- 2019-02-15 EC ECSENADI201911185A patent/ECSP19011185A/en unknown
- 2019-02-15 CO CONC2019/0001367A patent/CO2019001367A2/en unknown
-
2022
- 2022-05-02 JP JP2022075664A patent/JP2022105138A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
TN2019000015A1 (en) | 2020-07-15 |
CR20190072A (en) | 2019-06-25 |
AR109264A1 (en) | 2018-11-14 |
CA3030943A1 (en) | 2018-01-25 |
US20190241657A1 (en) | 2019-08-08 |
BR112019000770A2 (en) | 2019-07-02 |
MX2019000844A (en) | 2019-07-04 |
EP3484924A1 (en) | 2019-05-22 |
AU2017299125A1 (en) | 2019-03-07 |
PH12019500122A1 (en) | 2019-04-15 |
JP2019531701A (en) | 2019-11-07 |
DOP2019000011A (en) | 2019-05-15 |
PE20190514A1 (en) | 2019-04-10 |
EA201990321A1 (en) | 2019-06-28 |
JP2022105138A (en) | 2022-07-12 |
CN109715665A (en) | 2019-05-03 |
ECSP19011185A (en) | 2019-02-28 |
IL264248A (en) | 2019-02-28 |
TW201811830A (en) | 2018-04-01 |
CO2019001367A2 (en) | 2019-02-19 |
CL2019000119A1 (en) | 2019-06-14 |
JP7071329B2 (en) | 2022-05-18 |
MA45680A (en) | 2019-05-22 |
WO2018015340A1 (en) | 2018-01-25 |
KR20190028771A (en) | 2019-03-19 |
TWI790206B (en) | 2023-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201900400QA (en) | Bispecific antibody-like binding proteins specifically binding to cd3 and cd123 | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201811115TA (en) | Optimized mini-dystrophin genes and expression cassettes and their use | |
SG11201901899PA (en) | Bispecific trivalent antibodies binding to claudin6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases | |
SG11201805268XA (en) | T cell receptors specific for the ny-eso-1 tumor antigen-hla-a*02 complex | |
SG11201811603WA (en) | Novel adeno-associated virus capsid proteins | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201811338VA (en) | A novel botulinum neurotoxin and its derivatives | |
SG11201909022PA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
SG11201807279QA (en) | Binding proteins and methods of use thereof | |
SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
SG11201408679XA (en) | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof | |
SG11201908238SA (en) | Anti-c5 antibodies and uses thereof | |
SG11201408746XA (en) | Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides | |
SG11201407866XA (en) | Method for expression of heterologous proteins using a recombinant negative-strand rna virus vector | |
SG11201406903SA (en) | Cell culture compositions and methods for polypeptide production | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
SG11201809252YA (en) | Methods for determining dpp3 and therapeutic methods | |
SG11201909520VA (en) | Rna for treatment of autoimmune diseases | |
SG11201805497QA (en) | Mutated truncated von willebrand factor | |
SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
SG11201803642WA (en) | Bacteria-based protein delivery | |
SG11202000077RA (en) | Methods of treating behavior alterations |